167 related articles for article (PubMed ID: 33046990)
1. Landscape of
Zuo W; He Y; Li W; Wu H; Zhao Z; Zhang Y; Chen S; Yin Y
J Cancer; 2020; 11(22):6695-6699. PubMed ID: 33046990
[No Abstract] [Full Text] [Related]
2. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.
Parish A; Schwaederle M; Daniels G; Piccioni D; Fanta P; Schwab R; Shimabukuro K; Parker BA; Helsten T; Kurzrock R
Cell Cycle; 2015; 14(13):2121-8. PubMed ID: 25950492
[TBL] [Abstract][Full Text] [Related]
3. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.
Wheler JJ; Atkins JT; Janku F; Moulder SL; Stephens PJ; Yelensky R; Valero V; Miller V; Kurzrock R; Meric-Bernstam F
Oncoscience; 2016; 3(5-6):164-72. PubMed ID: 27489863
[TBL] [Abstract][Full Text] [Related]
4. Landscape of
Xu G; Zheng J; Wang S; Wang Y; Li G; Wang N; She X; Duan W; Zhang H; Huang D; Bei T; Fu D; Yang J
Ann Transl Med; 2022 Aug; 10(16):885. PubMed ID: 36110997
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive identification of
Gu W; Yang J; Wang Y; Xu J; Wang X; Du F; Hu X; Guo H; Song C; Tao R; Zhang X
Am J Cancer Res; 2021; 11(8):3893-3906. PubMed ID: 34522456
[TBL] [Abstract][Full Text] [Related]
7. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
8. Future applications of FGF/FGFR inhibitors in cancer.
Ghedini GC; Ronca R; Presta M; Giacomini A
Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
10. Targeting the FGF/FGFR axis and its co-alteration allies.
Uehara Y; Ikeda S; Kim KH; Lim HJ; Adashek JJ; Persha HE; Okamura R; Lee S; Sicklick JK; Kato S; Kurzrock R
ESMO Open; 2022 Dec; 7(6):100647. PubMed ID: 36455506
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors.
Jardim DLF; Millis SZ; Ross JS; Lippman S; Ali SM; Kurzrock R
Oncologist; 2023 Feb; 28(2):e82-e91. PubMed ID: 36082904
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients.
Sun Y; Li G; Zhu W; He Q; Liu Y; Chen X; Liu J; Lin J; Han-Zhang H; Yang Z; Lizaso A; Xiang J; Mao X; Liu H; Gao Y
Ann Transl Med; 2020 Oct; 8(20):1290. PubMed ID: 33209870
[TBL] [Abstract][Full Text] [Related]
13. The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives.
Santolla MF; Maggiolini M
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33081025
[TBL] [Abstract][Full Text] [Related]
14. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R
Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer.
Sato T; Oshima T; Yoshihara K; Yamamoto N; Yamada R; Nagano Y; Fujii S; Kunisaki C; Shiozawa M; Akaike M; Rino Y; Tanaka K; Masuda M; Imada T
Oncol Rep; 2009 Jan; 21(1):211-6. PubMed ID: 19082464
[TBL] [Abstract][Full Text] [Related]
16. FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention.
Wang Y; Liu D; Zhang T; Xia L
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802841
[TBL] [Abstract][Full Text] [Related]
17. Biological Significance and Targeting of the FGFR Axis in Cancer.
Chioni AM; Grose RP
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830836
[TBL] [Abstract][Full Text] [Related]
18. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors.
Udayakumar TS; Klein RD; Maliner MS; Nagle RB; Bowden GT
Int J Cancer; 2001 Jan; 91(2):187-92. PubMed ID: 11146443
[TBL] [Abstract][Full Text] [Related]
20. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
